Physician profile
Melissa Smith
NPI 1598151169
$1,907.85
in general payments reported to CMS, 2019-2025
14 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $291 · 2023: $898 · 2024: $333 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,617.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,616.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $461.31 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $290.95 | 2023-2025 | Rexulti |
| Tris Pharma INC | $231.03 | 2022-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $204.23 | 2022-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $132.62 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $107.91 | 2022 | |
| Idorsia Pharmaceuticals US INC | $100.64 | 2023-2025 | Quviviq, Quviviq |
| Boston Scientific Corporation | $91.04 | 2022 | |
| Collegium Pharmaceutical, INC. | $81.96 | 2025 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $71.78 | 2023-2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $63.48 | 2024-2025 | Spravato |
| Lundbeck LLC | $36.67 | 2022-2023 | Rexulti |
| Vanda Pharmaceuticals INC. | $19.81 | 2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $14.42 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.